Prelude Capital Management, LLC Agenus Inc Transaction History

Prelude Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.63 - $1.14 $16,933 - $30,642	26,879 New	26,879 $22,000
Q1 2023 May 15, 2023	BUY	$1.45 - $2.95 $15,364 - $31,258	10,596 New	10,596 $16,000
Q1 2022 May 16, 2022	SELL	$2.35 - $3.47 $31,905 - $47,112	-13,577 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.92 - $5.74 $39,644 - $77,931	13,577 New	13,577 $44,000
Q2 2018 Aug 14, 2018	SELL	$2.26 - $4.65 $2,519 - $5,184	-1,115 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$3.51 - $6.04 $1,912 - $3,291	-545 Reduced 32.83%	1,115 $5,000
Q4 2017 Feb 14, 2018	SELL	$3.26 - $4.78 $8,195 - $12,016	-2,514 Reduced 60.23%	1,660 $5,000
Q3 2017 Nov 14, 2017	BUY	$3.48 - $4.44 $14,525 - $18,532	4,174	4,174 $18,000

2.03M

Ticker AGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 283,163,008
Market Cap $4.73B
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs co...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.